KOSDAQBiotech & Pharma235980

MedPacto

₩3,735▼ 2.73%2026-11-18 close
Market Cap
₩128B
Turnover
₩1.2B
Volume
310K
Shares out.
34.3M
PER
—
PBR
4.1×
EPS
-₩389
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

MedPacto: Pipeline Expansion Amid Continued Losses

MedPacto is widening its pipeline beyond Vactosertib toward clinical and licensing steps for MP010 and MP2021, while its disclosed results still show operating losses across the last five quarters.

  1. 1

    An FDA-approved change in October 2026 added a 200mg mid-dose arm to the Vactosertib osteosarcoma Phase 2 trial.

  2. 2

    Revenue in 2025 was KRW 3.9 billion, above the KRW 3 billion level cited for listing maintenance, while the operating loss was KRW 14 billion and the net loss attributable to controlling shareholders was KRW 12.8 billion.

  3. 3

    Net losses attributable to controlling shareholders over the latest four quarters totaled KRW 13.3 billion, so PER is not calculated.

  4. 4

    MP010 is ahead of an IND filing planned for early 2027, and its pancreatic cancer animal-model study was selected as a cover paper in the November issue of Cancer Cell.

  5. 5

    Total equity stood at KRW 46 billion at the end of 2025 against total liabilities of KRW 2.68 billion, while operating cash outflow narrowed from -KRW 29.6 billion in 2022 to -KRW 13.4 billion in 2025.

02

Business structure

MedPacto was founded in 2013 as a spin-off from the drug discovery unit of Terragenetex and focuses on developing anticancer drugs.

Its lead pipeline is Vactosertib (development code TEW-7197), an oral TGF-β receptor (ALK5) inhibitor that the company has pursued in combination strategies to raise the effect of existing therapies in tumors that respond poorly to immuno-oncology drugs.

The company has recently focused on rare cancers such as osteosarcoma, and in the Phase 1 osteosarcoma trial of Vactosertib, an objective response rate (ORR) of 36.4% was reported among 11 patients with relapsed or refractory disease. The second axis is next-generation pipeline.

MP010 is an Fc bifunctional fusion protein immuno-oncology candidate that targets EDB-FN and TGF-β at the same time, while MP2021 is a bone disease candidate aimed at the novel target TM4SF19 as a first-in-class molecule.

MP2021 was submitted to Australia's human research ethics committee for a Phase 1 trial in July 2026, and reports followed that it had received approval.

Vactosertib was mostly tested in combination with immuno-oncology drugs such as Keytruda and Imfinzi, and critics say those designs did not establish monotherapy efficacy and did not lead to licensing deals.

Revenue comes from pharmaceutical distribution, genomic analysis and health functional food businesses, and the company said in its 2025 results announcement that this revenue allowed it to meet listing maintenance requirements.

The company is a drug developer, but its revenue base relies on distribution and food businesses separate from its clinical development work.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.2B-₩4.7B−395.4%
2025Q4₩1.4B-₩2.9B−204.4%
2026Q1₩1.3B-₩4.2B−316.6%
2026Q2₩1B-₩3.6B−346.2%
2026Q3₩1B-₩3.6B−362.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩0-₩37.2B-₩35.8B—−110.6%233.2%
2023₩0-₩28.8B-₩35.3B—−49.8%13.5%
2024₩0-₩21.8B-₩20.1B—−34.9%5.3%
2025₩3.9B-₩14B-₩12.8B−359.6%−27.9%5.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue is confirmed as a disclosed result only for 2025, at 39 eok won (1 eok = 100 million won), and there is no revenue data from the periodic reports for 2022 through 2024.

The operating loss was 372 eok won in 2022, 288 eok won in 2023, 218 eok won in 2024 and 140 eok won in 2025, so the loss narrowed every year, and the 2025 operating margin is -359.6%.

Net loss attributable to controlling shareholders fell from 358 eok won in 2022 to 353 eok won in 2023, 201 eok won in 2024 and 128 eok won in 2025, and net loss including non-controlling interests was disclosed at the same amounts for the same years.

The gap between operating loss and net loss differs from year to year, which suggests that non-operating items had a large effect, but the details are not in this results table.

Cash flow from operating activities was -296 eok won in 2022, -263 eok won in 2023, -166 eok won in 2024 and -134 eok won in 2025, so the cash outflow shrank. The debt ratio (total liabilities ÷ total equity) fell from 233.2% in 2022 to 13.5% in 2023 and 5.3% in 2024, then rose slightly to 5.8% in 2025.

At the end of 2025, total equity was 460 eok won, all of which was equity attributable to controlling shareholders, and total liabilities were 26.8 eok won.

Quarterly revenue rose to 12 eok won in Q3 2025 and 14.3 eok won in Q4 2025, then fell to 13.2 eok won in Q1 2026, 10.5 eok won in Q2 and 10 eok won in Q3, and Q3 2026 revenue was down 16.3% from the same period a year earlier.

Quarterly operating loss fell from 47.4 eok won in Q3 2025 to 29.2 eok won in Q4, then came in at 41.7 eok won in Q1 2026, 36.3 eok won in Q2 and 36.3 eok won in Q3.

Because the operating losses for Q2 and Q3 2026 are disclosed at the same 36.3 eok won, it is more accurate to look at the amounts themselves than at the direction between quarters.

Net loss attributable to controlling shareholders was 45.2 eok won in Q3 2025, 26.7 eok won in Q4, 37.6 eok won in Q1 2026, 31.9 eok won in Q2 and 37.2 eok won in Q3, and the total for the most recent four quarters is 133 eok won.

While revenue was declining, the quarterly operating loss in 2026 stayed between 36 eok won and 42 eok won, so an improvement in profit and loss is not yet confirmed in the figures. The disclosed results table identifies no items as one-off.

05

Industry analysis

TGF-β signaling inhibitors have been studied as a way to overcome resistance to immuno-oncology drugs, yet an April 2026 report noted that this is a path global big pharma companies have abandoned.

Vactosertib has been tested mostly in combination with immuno-oncology drugs such as Keytruda and Imfinzi, and a August 2025 analysis by Mirae Asset Securities pointed to combination designs that were not used to establish monotherapy efficacy.

Osteosarcoma is a rare cancer with limited treatment options, and Vactosertib holds FDA Fast Track designation, which raises the possibility of early approval based on Phase 2 data. Agenus's AGEN-1721 has been cited as a competing pipeline for MP010, and as of a 2025 report it was also at the preclinical stage.

Competition around PD-1xVEGF bispecific antibodies is intensifying, and Mirae Asset Securities noted in August 2025 that adding TGF-β to such combinations could be a point of interest. MP2021 is the second candidate after Vactosertib to reach clinical trials at MedPacto.

Compared with large listed peers in the sector such as Samsung Biologics and Celltrion, MedPacto has a smaller revenue base and a business centered on clinical development. As of a July 2026 report, Vactosertib had not yet produced a licensing deal, and calls to diversify the later-stage pipeline have grown.

As candidates move from preclinical work into the clinic, licensing terms with global pharmaceutical companies will shape how the business is commercialized.

06

Outlook

An FDA-approved change in October 2026 added a 200mg twice-daily mid-dose arm to the Vactosertib osteosarcoma Phase 2 trial, and Korea's Ministry of Food and Drug Safety approved the same change in September 2026.

The trial is running in Korea and the United States at the same time, with the aim of comparing treatment response across doses to identify the best dose. In February 2026, the company said initial Phase 2 data could be seen as early as the first half of 2026.

The company has described the 36.4% objective response rate in the Phase 1 osteosarcoma trial as more than three times that of existing therapies.

For MP010, the company said its evaluation in three pancreatic cancer animal models showed cure rates of 75.0% to 87.5% and long-term survival of 87.5%, but these are animal results, and efficacy and safety in humans must be confirmed in clinical trials.

Timing for the MP010 IND filing has moved from the late 2026 target stated in July 2026 to early 2027 in a November 2026 company statement. MP010 was presented to global pharmaceutical companies at BIO Japan in October 2026 and BIO-Europe in November 2026, and the commercialization approach has not yet been decided.

For MP2021, the company plans to confirm safety and tolerability in healthy adults in its Australian Phase 1 trial and then pursue early licensing.

MedPacto is in the process of advancing its pipeline into clinical stages with MP010 and MP2021, and whether licensing agreements are signed will be a key marker of its next business results.

07

Valuation

PER
—
PBR
4.1×
ROE
-31.7%
EPS
-₩389
BPS
₩1,045
Dividend per share
₩0

Because net losses attributable to controlling shareholders continue over the latest four quarters, PER is not calculated. Price-to-book ratio sits at a premium to net asset value, with equity of KRW 46 billion, so pipeline expectations appear to account for more of the share price than book value does.

The dividend yield is below the industry average. The stock has previously seen its market capitalization rise sharply and then fall, so multiples have varied widely across periods. After the November 11, 2026 report on MP010 preclinical results, the share price rose to the daily limit, which increased volatility. How the multiples are read depends on whether earnings-based measures or pipeline stage are given more weight.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Osteosarcoma data and dose expansion

In the Phase 1 osteosarcoma trial of Vactosertib, the objective response rate among 11 patients with relapsed or refractory disease was reported at 36.4%.

The program holds FDA Fast Track designation, and an October 2026 FDA-approved change added a mid-dose arm to the Phase 2 design for comparing dose-specific responses. The company said the mid-dose group showed comparatively better response in Phase 1.

Next-generation pipeline reaching the clinic

MP2021 was reported in July 2026 to have received approval for a Phase 1 trial in Australia, and it targets TM4SF19 as a first-in-class molecule.

MP010 is a bifunctional fusion protein that targets EDB-FN and TGF-β at the same time, and its preclinical results were selected as a cover paper in the November issue of Cancer Cell. Both candidates are approaching clinical entry, which moves the pipeline to a more advanced stage.

Financial capacity and listing requirements

Total equity at the end of 2025 was KRW 46 billion, with KRW 46 billion attributable to controlling shareholders, and total liabilities were KRW 2.68 billion. The debt ratio fell to 5.8% in 2025 from 233.2% in 2022.

The company said 2025 revenue of KRW 3.9 billion above the KRW 3 billion level cited for listing maintenance addressed concerns about administrative issue designation.

09

Bear factors

Operating losses alongside falling revenue

The 2025 operating loss was KRW 14 billion, the net loss attributable to controlling shareholders was KRW 12.8 billion, and the operating margin was -359.6%.

Quarterly revenue has fallen across three consecutive quarters of 2026 after peaking in the fourth quarter of 2025, and third-quarter 2026 revenue was down 16.3% from a year earlier.

Net losses attributable to controlling shareholders over the latest four quarters total KRW 13.3 billion, and a shift to profit is not yet visible in the disclosed results.

No licensing deal yet

A July 2026 report noted that Vactosertib, despite years of development, has not yet produced a licensing deal. MP010 was discussed with global pharmaceutical companies at BIO Japan and BIO-Europe in 2026, but the commercialization approach has not been set. Without a licensing agreement, clinical costs remain for the company to fund from its own resources.

Clinical uncertainty and cash outflows

The osteosarcoma response rate comes from a Phase 1 dataset of 11 patients, and the MP010 cure rates are from animal experiments. Vactosertib's combination trials have been criticized for not yet establishing monotherapy efficacy.

Operating cash flow was -KRW 13.4 billion in 2025, a smaller outflow but still negative, and quarterly operating losses in 2026 have remained above KRW 3.6 billion.

10

Risk factors

Clinical outcome risk

Initial Phase 2 data for Vactosertib in osteosarcoma were expected by the company in the first half of 2026, and the timing and results of disclosure could change how the program is judged.

MP010 and MP2021 have not yet been tested in humans for safety and efficacy, since they are at or near the start of clinical development. The gap between animal data and clinical results remains a possibility to monitor.

Trading flow and share price volatility risk

In late July 2026 the company said recent sharp share price moves reflected temporary trading flows from concentrated trades in a small number of accounts. On November 11, 2026 the share price rose to the daily limit after reports on MP010 preclinical results.

Share price movement has repeatedly responded to events and trading flows more than to reported business results.

Financial and listing requirement risk

Revenue of KRW 3.9 billion in 2025 exceeded the KRW 3 billion level cited for listing maintenance, but because the revenue base depends on distribution and food businesses, whether this continues must be confirmed in the next regular report.

Quarterly revenue has declined over three consecutive quarters and operating losses persist. Even with total equity of KRW 46 billion, continued operating cash outflows could increase the need for additional funding.

11

What to watch next

  1. After December 2026 · timing set by company disclosure

    Whether initial Phase 2 data for Vactosertib in osteosarcoma are released, and the response in the mid-dose arm. Dose-specific differences could change how the monotherapy approach is assessed relative to earlier combination strategies.

  2. Early 2027

    Whether the MP010 Phase 1 IND is submitted. A filing had been flagged for November to December 2026 in July, but in November a company official said submission is planned for early next year, so the actual filing date is the next checkpoint.

  3. End of March 2027 (annual report filing deadline)

    The 2026 annual report. It will show how annual revenue moves from KRW 3.9 billion in 2025, along with the operating loss and whether listing maintenance requirements are met.

  4. Date not set · timing set by company disclosure

    Progress of the MP2021 Phase 1 trial in Australia and the outcome of early licensing talks. A signed licensing agreement would be the first concrete sign of how the next-generation pipeline will be commercialized.

12

Overall view

XX

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. m.news.nate.com
  2. mt.co.kr
  3. supple.kr
  4. medpacto.com
  5. medicopharma.co.kr
  6. mt.co.kr
  7. etoday.co.kr
  8. mt.co.kr
  9. hankyung.com
  10. news.nate.com
  11. edaily.co.kr
  12. newspim.com
  13. fnnews.com
  14. press9.kr
  15. newspim.com
  16. pharmnews.com
  17. newsis.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis